Drug Trial Radar · NCT07304440
Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Jun 15, 2028
Study completion Jun 15, 2028
Sponsor
- Lead sponsor
- Adia Med of Winter Park LLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 12-month study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3-12. About 100 children with confirmed autism will be randomly assigned to one of two groups. One group receives monthly IV AdiaVita plus IV glutathione for 3 months. The other group receives IV glutathione plus a saline placebo infusion for 2 months. Both groups also use a topical glutathione spray twice a day at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC), completed by a parent and by a therapist or teacher. Safety is monitored at clinic visits through Month 12. Children who first receive glutathione only, may crossover to receive AdiaVita at no extra cost if they stay medically stable and their family agrees. Participation is voluntary. The study fee is $12,000.
Conditions
- Autism Spectrum Disorder
- Autism
- ASD
- Autism Spectrum Disorder (ASD)
Interventions
Umbilical Cord Blood-Derived Stem Cells and ExosomesBiological
Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes.
GlutathioneDrug
Reduced L-glutathione administered Intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6Time frame: Baseline and Month 6
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Adia Med Of Winter Park
Winter Park, Florida · Recruiting
The Lyday Center
Green Bay, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.